trial

Evaluation Study of New Compounds With Potential Use in Schizophrenia

NCTId NCT00916201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Withdrawn
Enrollment 0 (actual)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2025-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2025-01-31
Primary completion
2025-01-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
URB597Intranasal InsulinCannabidiol

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor
Max Planck Institute for Metabolism ResearchCollaborator

Investigators

1
F. Markus Leweke, MDPrincipal Investigator

Sites

1 total
Mannheim, Germany

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE1
Primary Completion Date
2025-01-31
Status
WITHDRAWN
relationships
The graph out of here
drug
URB597
drug
Intranasal Insulin
drug
Cannabidiol
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
collaborator
Max Planck Institute for Metabolism Research
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
F. Markus Leweke, MD
person